Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.44 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.42 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.42 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174921 | 0.82 | PSMB5 (0.62) | PSMB5PSMB1PSMB2ELANECTSG | |
| SCHEMBL12754502 | 0.82 | PSMB5 (0.62) | PSMB5PSMB1PSMB2ELANECTSG | |
| SCHEMBL3170833 | 0.82 | PSMB5 (0.62) | PSMB5PSMB1PSMB2ELANECTSG | |
| SCHEMBL608496 | 0.79 | EPHX1 (0.56) | EPHX1SMN1; SMN2MMP8ASAH2 | |
| SCHEMBL608495 | 0.76 | EPHX1 (0.52) | EPHX1SMN1; SMN2MMP8ASAH2 | |
| SCHEMBL16024778 | 0.73 | PSMB5 (0.51) | PSMB5PSMB1PSMB2ELANECTSG | |
| SCHEMBL20542992 | 0.73 | EPHX1 (0.63) | EPHX1SMN1; SMN2MMP8 | |
| SCHEMBL20542990 | 0.73 | EPHX1 (0.63) | EPHX1SMN1; SMN2MMP8 | |
| SCHEMBL20542669 | 0.73 | EPHX1 (0.63) | EPHX1SMN1; SMN2MMP8 | |
| SCHEMBL20542668 | 0.73 | EPHX1 (0.63) | EPHX1SMN1; SMN2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8546608-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | EPHX1 2993/4885PSMB5 2/4885SMN1; SMN2 1107/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | EPHX1 2993/4885PSMB5 2/4885SMN1; SMN2 1107/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | EPHX1 2993/4885PSMB5 2/4885SMN1; SMN2 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.